<DOC>
	<DOCNO>NCT00870974</DOCNO>
	<brief_summary>Measurement metabotropic glutamate receptor type 5 ( mGluR5 ) binding capacity brain , may valuable tool early detection , understanding , evaluation Parkinson disease ( PD ) , Huntington disease ( HD ) , Fragile X syndrome ( FXS ) , Autism Spectrum Disorder ( ASD ) , Alzheimer 's Disease ( AD ) , subject mild cognitive impairment ( MCI ) . The goal study ass [ 18F ] F-PEB positron emission tomography ( PET ) image tool detect mGluR5 density brain PD , HD , FXS ASD , AD , MCI research participant similarly age healthy subject .</brief_summary>
	<brief_title>A PET Brain Imaging Study mGluR5 Subjects With Neuropsychiatric Conditions</brief_title>
	<detailed_description>Informed consent obtain subject . All subject undergo screen evaluation include baseline clinical laboratory testing , baseline physical neurological evaluation baseline cognitive evaluation . All subject undergo [ 18F ] F-PEB PET image . Subjects may also ask undergo standard brain MRI assist analysis PET image obtain .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Written informed consent must obtain For female childbearing potential , negative urine blood pregnancy test day [ 18F ] PEB injection . INCLUSION CRITERIA : PD subject : Age 30 year old . Clinical diagnosis PD least two three cardinal symptom PD ( rest tremor , rigidity , bradykinesia ) Hoehn Yahr [ 35 ] ≤ 4 . HD subject : Age 18 year old . Participants clinical diagnosis symptomatic HD genetic confirmation Subject able provide inform consent judged investigator , assent obtain subject informed consent provide appropriate legal representative next kin . Healthy volunteer 18 year age older negative history neurological psychiatric illness . ASD and/or FRAGILE X : Age 18 year old Clinical diagnosis ASD and/or FXS Diagnosis FXS base gene test diagnosis ASD base DSMIV criterion AD subject : Participants positive assessment dementia Alzheimer type accordance DSMIVTR probable AD accord NINCDSADRDA criterion . Participants fulfill ICC criterion probable DLB , NINDSAIREN probable vascular dementia , Neary criterion FTD . CDR score 0.5 , 1 2 . MCI subject : Participants must complaint memory loss , objective impairment least one cognitive domain , essentially preserved activity daily live , meet diagnostic criterion AD form dementia . Participants fulfill ICC criterion probable DLB , NINDSAIREN probable vascular dementia , Neary criterion FTD . CDR score ≤ 0.5 . AD MCI : Age 50 year old . MRI brain scan finding reveal change indicative stroke and/or generalize cerebrovascular disease . Exclusion criterion may waive , judgment investigator ( 1 ) vascular dementia clinically unlikely ( 2 ) subject deem unable tolerate MRI procedure due claustrophobia , etc . EXCLUSION CRITERIA : PD , HD ASD and/or Fragile X subject : Clinically significant abnormal laboratory value and/or clinically significant unstable medical psychiatric illness Any disorder may interfere drug absorption distribution , metabolism , excretion ( include significant gastrointestinal surgery ) . Evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , alternative neurological , immunodeficiency , pulmonary , disorder disease . Clinically significant evidence vascular disease alternative neurologic disorder Healthy volunteer : Clinically significant abnormal laboratory value and/or clinically significant unstable medical psychiatric illness . Any disorder may interfere drug absorption distribution , metabolism , excretion ( include significant gastrointestinal surgery ) . Evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , neurological , immunodeficiency , pulmonary , disorder disease . AD MCI subject : The subject clinically significant abnormal laboratory value and/or clinically significant unstable medical psychiatric illness The subject disorder may interfere drug absorption distribution , metabolism , excretion ( include significant gastrointestinal surgery ) . The subject evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , alternative neurological , immunodeficiency , pulmonary , disorder disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson</keyword>
	<keyword>Huntington 's</keyword>
	<keyword>Fragile X</keyword>
	<keyword>Autistic Spectrum</keyword>
	<keyword>Alzheimer 's</keyword>
	<keyword>MCI</keyword>
</DOC>